ArticleMedical oncology (Northwood, London, England)2026

Site-specific trastuzumab Fab-DM1 via butelase-1 with ABD fusion for potent HER2-positive tumor control.

Yiming Han et al.PubMed ↗Publisher ↗

No numbers read from the abstract.